{"transactions":[{"id":4639097,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-13T14:08:17.000Z","date":"2026-10-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":192,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":156,"exercise_date":"2022-11-17","expiration_date":"2032-11-16","underlying":"Common Stock","underlying_shares":192},"source":{"system":"sec-edgar","filing":"0001331860-26-000005","document":"form4-10132026_021014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000005/form4-10132026_021014.xml","form_type":"4"}},{"id":4639096,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-13T14:08:17.000Z","date":"2026-10-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":247.2,"exercise_date":"2021-09-23","expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":121},"source":{"system":"sec-edgar","filing":"0001331860-26-000005","document":"form4-10132026_021014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000005/form4-10132026_021014.xml","form_type":"4"}},{"id":4639095,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-13T14:08:17.000Z","date":"2026-10-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":472.8,"exercise_date":"2020-09-16","expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":63},"source":{"system":"sec-edgar","filing":"0001331860-26-000005","document":"form4-10132026_021014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000005/form4-10132026_021014.xml","form_type":"4"}},{"id":4639094,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-13T14:08:17.000Z","date":"2026-10-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":128,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":232.8,"exercise_date":"2019-09-06","expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":128},"source":{"system":"sec-edgar","filing":"0001331860-26-000005","document":"form4-10132026_021014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000005/form4-10132026_021014.xml","form_type":"4"}},{"id":4639093,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-13T14:08:17.000Z","date":"2026-10-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":400.8,"exercise_date":"2018-09-27","expiration_date":"2028-09-26","underlying":"Common Stock","underlying_shares":74},"source":{"system":"sec-edgar","filing":"0001331860-26-000005","document":"form4-10132026_021014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000005/form4-10132026_021014.xml","form_type":"4"}},{"id":4639092,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-13T14:08:17.000Z","date":"2026-10-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":54,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction."}],"balance_after":0,"derivative":{"exercise_price":549.6,"exercise_date":"2017-06-08","expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":54},"source":{"system":"sec-edgar","filing":"0001331860-26-000005","document":"form4-10132026_021014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000005/form4-10132026_021014.xml","form_type":"4"}},{"id":4622865,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T20:11:03.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":78947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027."}],"balance_after":78947,"derivative":{"exercise_price":0.38,"expiration_date":"2036-09-16","underlying":"Common Stock","underlying_shares":78947},"source":{"system":"sec-edgar","filing":"0001331860-26-000003","document":"form4-09182026_080958.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1331860/000133186026000003/form4-09182026_080958.xml","form_type":"4"}},{"id":772914,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:49:29.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":18250,"source":{"system":"sec-edgar","filing":"0000905148-26-002532","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002532/form4.xml","form_type":"4"}},{"id":932203,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:30:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":5.79,"underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0000905148-26-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000320/form4.xml","form_type":"4"}},{"id":932202,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:30:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":9.18,"underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000905148-26-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000320/form4.xml","form_type":"4"}},{"id":932201,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:30:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":11.35,"underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000905148-26-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000320/form4.xml","form_type":"4"}},{"id":932200,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:30:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":3,"underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0000905148-26-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000320/form4.xml","form_type":"4"}},{"id":932199,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:30:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."}],"balance_after":0,"derivative":{"exercise_price":12.24,"underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0000905148-26-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000320/form4.xml","form_type":"4"}},{"id":1105618,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:34:32.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":17647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026."}],"balance_after":17647,"derivative":{"exercise_price":1.7,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":17647},"source":{"system":"sec-edgar","filing":"0001415889-25-017870","document":"form4-06202025_080628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000141588925017870/form4-06202025_080628.xml","form_type":"4"}},{"id":1113252,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T19:12:31.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":26550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":26550,"derivative":{"exercise_price":5.79,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0001104659-25-059034","document":"tm2517800-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465925059034/tm2517800-4_4seq1.xml","form_type":"4"}},{"id":1132347,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:06.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001933","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001933/form4.xml","form_type":"4"}},{"id":1132346,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:06.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000905148-25-001933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001933/form4.xml","form_type":"4"}},{"id":1333153,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-13T21:23:34.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":8646,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of March 12, 2025, June 12, 2025, September 12, 2025 and December 12, 2025."}],"balance_after":8646,"derivative":{"exercise_price":3.47,"expiration_date":"2034-12-12","underlying":"Common Stock","underlying_shares":8646},"source":{"system":"sec-edgar","filing":"0001415889-24-029300","document":"form4-12132024_091231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000141588924029300/form4-12132024_091231.xml","form_type":"4"}},{"id":1488311,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:07:49.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2024 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":14100,"derivative":{"exercise_price":9.18,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001104659-24-069076","document":"tm2416582-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924069076/tm2416582-7_4seq1.xml","form_type":"4"}},{"id":1499444,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T23:20:45.000Z","date":"2024-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":0.9075,"expiration_date":"2034-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905148-24-001654","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001654/form4.xml","form_type":"4"}},{"id":1499443,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-29T23:20:45.000Z","date":"2024-05-25","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000905148-24-001654","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001654/form4.xml","form_type":"4"}},{"id":1710314,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-15T21:10:12.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":38136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024."}],"balance_after":38136,"derivative":{"exercise_price":0.59,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":38136},"source":{"system":"sec-edgar","filing":"0001415889-23-016526","document":"form4-12152023_041202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000141588923016526/form4-12152023_041202.xml","form_type":"4"}},{"id":1831094,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T22:45:40.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":1.32,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-23-034286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034286/form4.xml","form_type":"4"}},{"id":1831093,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-12T22:45:40.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001140361-23-034286","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034286/form4.xml","form_type":"4"}},{"id":1865098,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T08:06:37.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":14100,"derivative":{"exercise_price":11.35,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001104659-23-068342","document":"tm2317752-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465923068342/tm2317752-8_4seq1.xml","form_type":"4"}},{"id":2109359,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-21T21:30:25.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":46154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of February 17, 2023, May 17, 2023, August 17, 2023 and November 17, 2023."}],"balance_after":129747,"derivative":{"exercise_price":0.65,"expiration_date":"2032-11-16","underlying":"Common Stock","underlying_shares":46154},"source":{"system":"sec-edgar","filing":"0001415889-22-011629","document":"form4-11212022_091111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000141588922011629/form4-11212022_091111.xml","form_type":"4"}},{"id":2225307,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T08:32:00.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being made to show the correct price of $3.00. An incorrect price of $2.99 was previously reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":8333,"derivative":{"exercise_price":3,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001104659-22-072749","document":"tm2218796-2_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922072749/tm2218796-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-06-09"}},{"id":2237671,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-09T17:56:14.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":8333,"derivative":{"exercise_price":2.99,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001104659-22-069754","document":"tm2218033-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922069754/tm2218033-2_4seq1.xml","form_type":"4"}},{"id":2260451,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-23T21:50:24.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-05-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-22-020306","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020306/form4.xml","form_type":"4"}},{"id":2260450,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-23T21:50:24.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001140361-22-020306","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020306/form4.xml","form_type":"4"}},{"id":2560473,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-24T20:21:11.000Z","date":"2021-09-23","kind":"grant","acquired":true,"shares":29126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022."}],"balance_after":29126,"derivative":{"exercise_price":1.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":29126},"source":{"system":"sec-edgar","filing":"0001104659-21-119309","document":"tm2128426-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000110465921119309/tm2128426-2_4seq1.xml","form_type":"4"}},{"id":2686335,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T19:13:54.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2021 and is schedule to vest in equal annual installments over a three-year period from the date of grant, subject to the director's continued service."}],"balance_after":100000,"derivative":{"exercise_price":2.04,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-21-075899","document":"tm2118270-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465921075899/tm2118270-2_4seq1.xml","form_type":"4"}},{"id":2701342,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T00:55:53.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":3.64,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-21-005766","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005766/edgar.xml","form_type":"4"}},{"id":2701341,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-22T00:55:53.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-21-005766","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005766/edgar.xml","form_type":"4"}},{"id":3027397,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T20:36:18.000Z","date":"2020-09-16","kind":"grant","acquired":true,"shares":15228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021."}],"balance_after":15228,"derivative":{"exercise_price":1.97,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":15228},"source":{"system":"sec-edgar","filing":"0001213900-20-027374","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000121390020027374/ownership.xml","form_type":"4"}},{"id":3111800,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-12T11:45:12.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020 and is scheduled to vest in full on June 11, 2021."}],"balance_after":7500,"derivative":{"exercise_price":6.17,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-20-072735","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465920072735/a4.xml","form_type":"4"}},{"id":3147590,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-16T00:53:08.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.765,"expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001179110-20-006132","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/edgar.xml","form_type":"4"}},{"id":3418978,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-10T22:37:34.000Z","date":"2019-09-06","kind":"grant","acquired":true,"shares":30928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020."}],"balance_after":30928,"derivative":{"exercise_price":0.97,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":30928},"source":{"system":"sec-edgar","filing":"0001213900-19-017650","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000121390019017650/ownership.xml","form_type":"4"}},{"id":3512125,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-24T21:17:04.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":2.02,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001179110-19-006699","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/edgar.xml","form_type":"4"}},{"id":3653650,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-15T08:37:14.000Z","date":"2019-02-13","kind":"grant","acquired":true,"shares":12200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 13, 2019. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversay of the grant date until the third anniversary of the grant date."}],"balance_after":12200,"derivative":{"exercise_price":4.39,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":12200},"source":{"system":"sec-edgar","filing":"0001179110-19-001939","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911019001939/edgar.xml","form_type":"4"}},{"id":3703912,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-04T16:04:15.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This 4/A is being filed to correct the stated Conversion or Exercise Price of Derivative Security.  The correct Exercise Price of the Derivative Security is $4.60 and was previously stated at $4.90."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2019.  The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversary of the grant date until the third anniversary of the grant date."}],"balance_after":2800,"derivative":{"exercise_price":4.6,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001179110-19-000404","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911019000404/edgar.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":3703911,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-04T09:24:38.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 3, 2019. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversay of the grant date until the third anniversay of the grant date."}],"balance_after":2800,"derivative":{"exercise_price":4.9,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001179110-19-000343","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000117911019000343/edgar.xml","form_type":"4"}},{"id":3806246,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-28T21:04:50.000Z","date":"2018-09-27","kind":"grant","acquired":true,"shares":17964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019."}],"balance_after":17964,"derivative":{"exercise_price":1.67,"expiration_date":"2028-09-26","underlying":"Common Stock","underlying_shares":17964},"source":{"system":"sec-edgar","filing":"0001213900-18-013223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000121390018013223/ownership.xml","form_type":"4"}},{"id":3926187,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-19T01:29:15.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":3.98,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-18-007150","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/edgar.xml","form_type":"4"}},{"id":4175074,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-02T23:31:27.000Z","date":"2017-10-31","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services."}],"balance_after":80000,"derivative":{"exercise_price":3.8,"expiration_date":"2027-10-31","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001179110-17-013684","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911017013684/edgar.xml","form_type":"4"}},{"id":4186059,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":0.28,"value":8400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186058,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":2.03,"value":60900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016."}],"balance_after":0,"derivative":{"exercise_price":9.15,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186057,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":6.08,"value":182400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015."}],"balance_after":0,"derivative":{"exercise_price":5.1,"expiration_date":"2024-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186056,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":6.05,"value":181500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014."}],"balance_after":0,"derivative":{"exercise_price":5.13,"expiration_date":"2023-06-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186055,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":4.4,"value":132000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013."}],"balance_after":0,"derivative":{"exercise_price":6.78,"expiration_date":"2022-06-07","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186054,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":5.14,"value":154200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012."}],"balance_after":0,"derivative":{"exercise_price":6.04,"expiration_date":"2021-06-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186053,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":8.17,"value":245100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011."}],"balance_after":0,"derivative":{"exercise_price":3.01,"expiration_date":"2020-06-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186052,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":8.95,"value":44750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010."}],"balance_after":0,"derivative":{"exercise_price":2.23,"expiration_date":"2019-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4186051,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-16T17:11:05.000Z","date":"2017-10-13","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":9.94,"value":497000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the \"Merger\") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Under its terms the option became exercisable in installments at the rate of one-third of the shares subject to the option at the end of each anniversary of service as an outside director of the Issuer, beginning March 30, 2010, and became immediately exercisable and vested in full as of March 30, 2012."}],"balance_after":0,"derivative":{"exercise_price":1.24,"expiration_date":"2019-03-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-17-024255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/880771/000089924317024255/doc4.xml","form_type":"4"}},{"id":4286382,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-12T21:21:11.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":13100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018."}],"balance_after":13100,"derivative":{"exercise_price":2.29,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":13100},"source":{"system":"sec-edgar","filing":"0001213900-17-006381","document":"f4060817lapointe_soligenix.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000121390017006381/f4060817lapointe_soligenix.xml","form_type":"4"}},{"id":4287701,"issuer":{"id":172474,"kind":"organization","name":"SCICLONE PHARMACEUTICALS INC","symbol":"SCLN"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Board Member"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-06-09T16:23:47.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted under the Issuer's 2015 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer."}],"balance_after":30000,"derivative":{"exercise_price":10.9,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000880771-17-000097","document":"certent-form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/880771/000088077117000097/certent-form4.xml","form_type":"4"}},{"id":4306891,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-05-24T20:35:45.000Z","date":"2017-05-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The option grant was approved by the issuer's board of directors on March 31, 2017, subject to stockholder approval of the amendment and restatement of the issuer's 2014 Equity Incentive Plan (the \"Restated Plan\") under which the option was granted. The issuer's stockholders approved the Restated Plan on May 22, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fifty percent (50%) of the option shares shall vest on March 31, 2018 with the remaining fifty percent (50%) of the option shares vesting on March 31, 2019."}],"balance_after":50000,"derivative":{"exercise_price":1.6,"expiration_date":"2027-03-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-034968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117034968/doc4.xml","form_type":"4"}},{"id":4574162,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-10-26T16:39:41.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":7915,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":5.22,"expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":7915},"source":{"system":"sec-edgar","filing":"0001140361-16-083649","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083649/doc1.xml","form_type":"4"}},{"id":4574161,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-26T16:39:41.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":8330,"price":9,"value":74970.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-16-083649","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083649/doc1.xml","form_type":"4"}},{"id":4574160,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":46093,"kind":"person","name":"LAPOINTE ANTHONY GREGG","position":1,"cik":"0001331860","reported_name":"LAPOINTE ANTHONY GREGG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-26T16:39:41.000Z","date":"2016-10-24","kind":"other","acquired":false,"shares":2092,"price":9,"value":18828.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. (\"Raptor\"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland (\"Parent\") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent."}],"balance_after":8330,"source":{"system":"sec-edgar","filing":"0001140361-16-083649","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083649/doc1.xml","form_type":"4"}}]}